PHR
Phreesia, Inc. NYSE Listed Jul 18, 2019$9.84
Mkt Cap $597.6M
52w Low $7.77
8.3% of range
52w High $32.76
50d MA $10.32
200d MA $18.54
P/E (TTM)
250.5x
EV/EBITDA
28.2x
P/B
1.7x
Debt/Equity
0.3x
ROE
0.7%
P/FCF
11.8x
RSI (14)
—
ATR (14)
—
Beta
0.85
50d MA
$10.32
200d MA
$18.54
Avg Volume
2.2M
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.
434 Fayetteville Street · Wilmington, NC 27601 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | 0.07 | 0.12 | +82.6% | 11.41 | -29.7% | -26.6% | -26.4% | -26.6% | -19.8% | -20.6% | — |
| Dec 8, 2025 | AMC | -0.00 | 0.10 | +9999.0% | 20.12 | -4.7% | -23.3% | -21.6% | -20.3% | -19.2% | -17.0% | — |
| Sep 4, 2025 | AMC | -0.07 | 0.01 | +114.3% | 31.21 | -7.1% | -9.9% | -14.2% | -14.9% | -18.8% | -18.4% | — |
| May 28, 2025 | AMC | -0.13 | -0.07 | +46.2% | 23.30 | +2.7% | +4.8% | +5.1% | +6.9% | +10.6% | +8.2% | — |
| Mar 12, 2025 | AMC | -0.19 | -0.11 | +42.1% | 23.80 | +1.0% | +6.9% | +6.9% | +13.2% | +14.6% | +21.8% | — |
| Dec 9, 2024 | AMC | -0.27 | -0.25 | +7.4% | 21.63 | +2.7% | +11.6% | +14.6% | +13.5% | +15.3% | +18.5% | — |
| Sep 4, 2024 | AMC | -0.37 | -0.31 | +16.2% | 24.17 | +1.4% | +6.3% | -2.6% | -1.1% | -2.2% | -3.5% | — |
| May 30, 2024 | AMC | -0.51 | -0.35 | +31.4% | 21.31 | -3.7% | -11.2% | -13.0% | -12.6% | -7.8% | -7.3% | — |
| Mar 14, 2024 | AMC | -0.58 | -0.56 | +3.4% | 22.67 | +3.6% | +4.8% | +1.2% | +2.2% | +6.8% | +4.0% | — |
| Dec 5, 2023 | AMC | -0.72 | -0.58 | +19.4% | 14.75 | +23.1% | +21.2% | +21.2% | +22.3% | +27.2% | +35.7% | — |
| Sep 6, 2023 | AMC | -0.75 | -0.68 | +9.3% | 30.35 | -11.8% | -22.1% | -27.8% | -27.9% | -29.9% | -33.5% | — |
| May 31, 2023 | AMC | -0.80 | -0.70 | +12.5% | 30.02 | -1.7% | +2.9% | +8.8% | +9.6% | +8.3% | +7.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $8.06 | $8.03 | -0.4% | +6.2% | +6.7% | +12.4% | +13.8% | +13.8% |
| Apr 1 | Citizens | Downgrade | Market Outperform → Market Perform | — | $8.38 | $8.40 | +0.2% | +0.2% | -0.1% | +9.2% | +8.1% | +4.4% |
| Mar 31 | Truist | Downgrade | Buy → Hold | — | $11.41 | $8.02 | -29.7% | -26.6% | -26.4% | -26.6% | -19.8% | -20.6% |
| Mar 31 | Needham | Maintains | Buy → Buy | — | $11.41 | $8.02 | -29.7% | -26.6% | -26.4% | -26.6% | -19.8% | -20.6% |
| Mar 31 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.41 | $8.02 | -29.7% | -26.6% | -26.4% | -26.6% | -19.8% | -20.6% |
| Mar 31 | BMO Capital | Maintains | Outperform → Outperform | — | $11.41 | $8.02 | -29.7% | -26.6% | -26.4% | -26.6% | -19.8% | -20.6% |
| Mar 31 | Baird | Downgrade | Outperform → Neutral | — | $11.41 | $8.02 | -29.7% | -26.6% | -26.4% | -26.6% | -19.8% | -20.6% |
| Mar 31 | Citigroup | Downgrade | Buy → Neutral | — | $11.41 | $8.02 | -29.7% | -26.6% | -26.4% | -26.6% | -19.8% | -20.6% |
| Mar 31 | Stephens & Co. | Maintains | Overweight → Overweight | — | $11.41 | $8.02 | -29.7% | -26.6% | -26.4% | -26.6% | -19.8% | -20.6% |
| Mar 31 | JP Morgan | Downgrade | Overweight → Neutral | — | $11.41 | $8.02 | -29.7% | -26.6% | -26.4% | -26.6% | -19.8% | -20.6% |
| Mar 26 | Wells Fargo | Maintains | Overweight → Overweight | — | $11.28 | $11.19 | -0.8% | +3.3% | -2.7% | +1.2% | -25.7% | -25.5% |
| Mar 24 | Mizuho | Maintains | Outperform → Outperform | — | $11.80 | $11.48 | -2.7% | -4.4% | -4.4% | -1.3% | -6.9% | -3.3% |
| Feb 20 | JP Morgan | Maintains | Overweight → Overweight | — | $12.58 | $12.50 | -0.6% | +1.0% | -7.0% | -7.3% | -6.0% | -2.0% |
| Jan 23 | DA Davidson | Maintains | Buy → Buy | — | $15.80 | $15.67 | -0.8% | +0.3% | -0.5% | -3.9% | -7.2% | -11.7% |
| Jan 9 | Citigroup | Maintains | Buy → Buy | — | $16.90 | $17.15 | +1.5% | +2.0% | +1.4% | -1.9% | -4.7% | -2.7% |
| Dec 16 | Barclays | Maintains | Overweight → Overweight | — | $16.70 | $16.52 | -1.1% | -2.1% | -2.4% | -1.7% | -0.9% | -1.4% |
| Dec 10 | Mizuho | Maintains | Outperform → Outperform | — | $15.43 | $15.69 | +1.7% | +2.3% | +4.0% | +5.3% | +8.2% | +6.0% |
| Dec 10 | Baird | Maintains | Outperform → Outperform | — | $15.43 | $15.69 | +1.7% | +2.3% | +4.0% | +5.3% | +8.2% | +6.0% |
| Dec 9 | Citigroup | Maintains | Buy → Buy | — | $20.12 | $19.18 | -4.7% | -23.3% | -21.6% | -20.3% | -19.2% | -17.0% |
| Dec 9 | JP Morgan | Maintains | Overweight → Overweight | — | $20.12 | $19.18 | -4.7% | -23.3% | -21.6% | -20.3% | -19.2% | -17.0% |
| Dec 9 | Needham | Maintains | Buy → Buy | — | $20.12 | $19.18 | -4.7% | -23.3% | -21.6% | -20.3% | -19.2% | -17.0% |
| Dec 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $20.12 | $19.18 | -4.7% | -23.3% | -21.6% | -20.3% | -19.2% | -17.0% |
| Dec 8 | Needham | Maintains | Buy → Buy | — | $20.29 | $20.84 | +2.7% | -0.8% | -24.0% | -22.2% | -20.9% | -19.9% |
| Dec 2 | DA Davidson | Maintains | Buy → Buy | — | $20.01 | $20.13 | +0.6% | +0.7% | +1.8% | +2.7% | +1.4% | +0.5% |
| Oct 8 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $23.41 | $23.28 | -0.6% | -0.7% | +1.8% | -4.9% | -5.0% | -2.2% |
| Sep 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $28.13 | $28.51 | +1.4% | -4.8% | -5.6% | -9.9% | -9.4% | -14.0% |
| Sep 8 | Truist | Maintains | Buy → Buy | — | $28.13 | $28.51 | +1.4% | -4.8% | -5.6% | -9.9% | -9.4% | -14.0% |
| Sep 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $31.21 | $28.99 | -7.1% | -9.9% | -14.2% | -14.9% | -18.8% | -18.4% |
| Sep 5 | Needham | Maintains | Buy → Buy | — | $31.21 | $28.99 | -7.1% | -9.9% | -14.2% | -14.9% | -18.8% | -18.4% |
| Sep 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $31.21 | $28.99 | -7.1% | -9.9% | -14.2% | -14.9% | -18.8% | -18.4% |
| Sep 3 | Stephens & Co. | Maintains | Overweight → Overweight | — | $31.48 | $31.58 | +0.3% | -3.3% | -0.9% | -10.6% | -14.9% | -15.7% |
| Jul 14 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $26.72 | $27.12 | +1.5% | +3.3% | +0.0% | +1.2% | -3.0% | -4.6% |
| May 29 | Truist | Maintains | Buy → Buy | — | $23.30 | $23.93 | +2.7% | +4.8% | +5.1% | +6.9% | +10.6% | +8.2% |
| May 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $23.30 | $23.93 | +2.7% | +4.8% | +5.1% | +6.9% | +10.6% | +8.2% |
| Apr 16 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $23.96 | $23.66 | -1.3% | -0.3% | +0.0% | -3.0% | -2.9% | +0.9% |
| Apr 14 | DA Davidson | Maintains | Buy → Buy | — | $24.06 | $24.43 | +1.5% | -1.0% | -0.4% | -0.7% | -0.4% | -3.4% |
| Mar 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $23.80 | $24.04 | +1.0% | +6.9% | +6.9% | +13.2% | +14.6% | +21.8% |
| Mar 13 | Needham | Maintains | Buy → Buy | — | $23.80 | $24.04 | +1.0% | +6.9% | +6.9% | +13.2% | +14.6% | +21.8% |
| Jan 29 | Piper Sandler | Maintains | Overweight → Overweight | — | $29.29 | $29.87 | +2.0% | -2.0% | -1.0% | -2.8% | -4.0% | -2.2% |
| Jan 10 | Needham | Maintains | Buy → Buy | — | $28.43 | $27.85 | -2.0% | -6.2% | -6.5% | -8.1% | -4.7% | -5.7% |
| Jan 10 | Citigroup | Maintains | Buy → Buy | — | $28.43 | $27.85 | -2.0% | -6.2% | -6.5% | -8.1% | -4.7% | -5.7% |
| Jan 8 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $26.98 | $27.67 | +2.6% | +5.4% | -1.1% | -1.5% | -3.2% | +0.4% |
| Jan 8 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $26.98 | $27.67 | +2.6% | +5.4% | -1.1% | -1.5% | -3.2% | +0.4% |
| Dec 11 | Baird | Maintains | Outperform → Outperform | — | $24.14 | $24.76 | +2.6% | +2.7% | +1.7% | +3.3% | +6.2% | +3.0% |
| Dec 11 | Truist | Maintains | Buy → Buy | — | $24.14 | $24.76 | +2.6% | +2.7% | +1.7% | +3.3% | +6.2% | +3.0% |
| Dec 10 | Needham | Maintains | Buy → Buy | — | $21.63 | $22.21 | +2.7% | +11.6% | +14.6% | +13.5% | +15.3% | +18.5% |
| Dec 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $21.63 | $22.21 | +2.7% | +11.6% | +14.6% | +13.5% | +15.3% | +18.5% |
| Sep 27 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $22.20 | $22.62 | +1.9% | +2.3% | +2.7% | +0.7% | +0.8% | -0.6% |
| Sep 9 | JP Morgan | Maintains | Overweight → Overweight | — | $23.55 | $23.65 | +0.4% | +1.5% | +0.3% | -1.0% | +0.9% | +4.8% |
| Sep 6 | Baird | Maintains | Outperform → Outperform | — | $25.69 | $26.33 | +2.5% | -8.3% | -6.9% | -8.0% | -9.2% | -7.5% |
No insider trades available.
8-K · 1.01
!! High
Phreesia, Inc. -- 8-K 1.01: Material Agreement
Phreesia secured financing through PNC Bank via an amended credit facility for its AccessOne MedCard subsidiary, expanding its financial flexibility for healthcare payment solutions operations.
May 4
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis as the excerpt only contains boilerplate forward-looking statement disclaimers with no substantive business information about PHR's actual events or developments.
Apr 3
8-K
Unknown — 8-K Filing
Phreesia reported Q4 FY2026 results showing its all-remote operating model, which could indicate higher margins and talent flexibility, potentially supporting profitability and growth investors should monitor in future quarters.
Mar 30
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
The company refinanced existing debt with Goldman Sachs and Capital One, potentially improving terms or extending maturity dates, which could reduce near-term financial pressure and refinancing risk.
Mar 16
8-K · 5.02
!!! Very High
Phreesia, Inc. -- 8-K 5.02: Executive Change
Phreesia is replacing two directors with Jon Kessler, signaling potential leadership evolution as Edward Cahill and Michael Weintraub exit the board effective April 2026.
Feb 23
Data updated apr 26, 2026 7:37pm
· Source: massive.com